BACKGROUND: Iron deficiency is present in >50% of patients with heart failure with preserved ejection fraction and is associated with reduced exercise capacity and survival. Whether iron repletion improves exercise capacity as objectively measured by peak oxygen uptake ([Formula: see text]) is unknown. The IRONMET-HFpEF trial (Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in HFpEF) sought to determine whether ferric derisomaltose (FDI) compared with placebo improves peak [Formula: see text] in heart failure with preserved ejection fraction with iron deficiency.
METHODS: This was a double-blind, placebo-controlled randomized clinical trial of patients with heart failure with preserved ejection fraction and iron deficiency, defined as ferritin <100 ng/mL or <300 ng/mL with transferrin saturation <20%. Participants were enrolled between December 2021 and April 2026. Single-dose ferric derisomaltose (1000 mg; n=44) or placebo (n=21) was administered once intravenously. The primary end point was the change in peak [Formula: see text] from baseline to 12 weeks with an analysis of covariance model including terms for treatment group, baseline peak [Formula: see text], and sex. Secondary end points included changes in [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, New York Heart Association class, health status assessed by the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score, and iron biomarkers at 12 weeks.
RESULTS: Among 65 randomized participants (median age, 68 years [interquartile range, 58-76 years], 72% women, transferrin saturation 16.0±7.4%, ferritin 57.8±48.9 ng/mL), 64 (98.5%) completed the study. The median baseline peak [Formula: see text] was 12.7 mL·kg-1·min-1 (interquartile range, 10.6-15.8 mL·kg-1·min-1) in the FDI group and 12.2 mL·kg-1·min-1 (11.6-14.6 mL·kg-1·min-1) in the placebo group. At 12 weeks, peak [Formula: see text] improved by 1.2 mL·kg-1·min-1 (95% CI, 0.6-1.7) in the FDI group and was unchanged (0.1 mL·kg-1·min-1 [95% CI, -0.7 to 0.9]) in the placebo group (least-squares mean difference, 1.1 mL·kg-1·min-1 [95% CI, 0.2-1.9]; P=0.02). [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, and New York Heart Association class also improved in the FDI compared with the placebo group (all P<0.05), whereas the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score did not differ significantly between groups (FDI group, +4.4 [95% CI, -2.4 to 11.2]; P=0.20). FDI increased transferrin saturation (9.4% [95% CI, 4.9%-13.9%]) and ferritin (183 ng/mL [95% CI, 128-238]) compared with the placebo group (PLSMD<0.001 for both). There were no serious adverse events related to FDI administration.
CONCLUSIONS: In the largest trial to date of iron repletion in heart failure with preserved ejection fraction with iron deficiency, FDI improved multiple measures of exercise capacity.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04945707.
| Discipline Area | Score |
|---|---|
| Cardiology | ![]() |
| Internal Medicine | ![]() |
| Family Medicine (FM)/General Practice (GP) | Coming Soon... |
| General Internal Medicine-Primary Care(US) | Coming Soon... |
This study is highly relevant because iron deficiency is common but often under-recognised in patients with HFpEF. The trial demonstrated clinically meaningful improvements in exercise capacity and functional status following a single intravenous iron infusion and had an excellent safety profile. Given the limited effect many existing HFpEF treatments have on exercise tolerance, these findings highlight a potentially important and practical management strategy that may influence future guidance and specialist practice.